Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. 2006

Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
Department of Internal Medicine, Chiba-Hokusoh Hospital, Nippon Medical School 1715 Kamakari, Imba, Chiba 270-1694, Japan.

OBJECTIVE The neointimal coverage and intracoronary thrombi within stented segments at 6 months after implantation between sirolimus-eluting stents (SESs) and bare metal stents (BMSs) were compared by direct visualization using angioscopy. RESULTS Forty-six patients (36 stable angina and 10 acute coronary syndrome) were treated with 33 SESs and 33 BMSs. Immediately after and 6 months after stenting, each of the stented segments, edge body, and overlapping segment were observed by angioscopy and the grade of neointimal coverage over the stents was classified as 0: absent neointima, 1: visible struts through thin neointima, or 2: invisible struts. The existence of thrombi was also evaluated. The average grade of the neointimal coverage at 6 months follow-up was lower in the SES than that in the BMS (edge: 1.4+/-0.7 vs. 1.9+/-0.2, body: 1.0+/-0.5 vs. 1.8+/-0.5, overlapping segment: 0.6+/-0.7 vs. 1.8+/-0.5; P<0.0001, P<0.0001, P=0.0069, respectively). The frequency of persistence of thrombus was significantly higher in the SESs than that in the BMSs (86 vs. 29%, respectively; P=0.031). CONCLUSIONS The present study suggested a delayed neointimal stent coverage and slower thrombus disappearance process in the SESs in comparison to the BMSs.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003328 Coronary Thrombosis Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION. Thrombosis, Coronary,Coronary Thromboses,Thromboses, Coronary
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D004343 Drug Implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug. Drug Implant,Drug Pellet,Pellets, Drug,Drug Pellets,Implant, Drug,Implants, Drug,Pellet, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
August 2007, Circulation,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
August 2008, Journal of the American College of Cardiology,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
May 2006, Journal of the American College of Cardiology,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
May 2008, Heart (British Cardiac Society),
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
May 2011, Clinical cardiology,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
August 2016, Circulation journal : official journal of the Japanese Circulation Society,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
December 2006, American heart journal,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
March 2008, Chinese medical journal,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
April 2007, European heart journal,
Masamichi Takano, and Takayoshi Ohba, and Shigenobu Inami, and Koji Seimiya, and Shunta Sakai, and Kyoichi Mizuno
January 2010, In vivo (Athens, Greece),
Copied contents to your clipboard!